

NewCures is a Northwestern biomedical accelerator that focuses on accelerating the development of potential therapeutics from University laboratories on the Evanston and Chicago campuses. Its mission is to strengthen Northwestern's therapeutic pipeline and to expedite the translational process of early-stage research discoveries into next generation therapeutics to ultimately benefit patients. By aligning and coordinating across the University, NewCures fills a translational gap in therapeutic development and aims to enhance and de-risk discoveries by: (1) identifying potential assets; (2) developing pertinent and robust preclinical data; and (3) translating research to industry-ready assets to attract external partnerships and investment. The programmatic structure of NewCures also serves to promote the exchange of knowledge related to pre-clinical therapeutic development at Northwestern.

BENEFITS

Selected projects will reap a number of benefits. NewCures will:


- Work with PIs and external experts to formulate a development plan, outlining key pre-clinical experiments for proof-of-concept validation;
- Outsource experimental work to third party contract research organizations (CRO), with related fees covered by NewCures;
- Translate research and collect new data that is "industry-ready"; and
- Engage corporate or venture players for future partnership and investment.

ELIGIBILITY

Intellectual property (IP) of selected projects must meet the following criteria:

- Must be owned by Northwestern;
- If IP is jointly owned, NU must be the lead, and joint owner must be a non-profit organization;
- Should cover Composition of Matter (issued or pending);
- Should have filed foreign coverage or be eligible for international protection; and
- Should not be licensed to a third party.

APPLICATION & APPROVAL PROCESS



PROJECT SELECTION

New therapeutic discoveries are submitted to INVO. NewCures will:

- Evaluate eligibility criteria;
- Prioritize Northwestern IPs based on INVO's established prioritization process;
- Identify assets at value inflection point; and
- Present the identified assets to NewCures Advisory Board.

To ensure a thorough yet unbiased selection process, the NewCures Advisory Board consisting of members from within and outside of the Northwestern community will collectively discuss the projects that are under consideration for NewCures support. Internal members are leaders from Northwestern scientific communities with experience in therapeutic translation. External members are highly recognized leaders with expertise in therapeutic development from pharmaceutical, biotech and investment industries. To avoid potential conflict of interest, Northwestern-affiliated board members will not have voting rights to determine which projects will be supported by NewCures. Only external members will be involved in the final selection of NewCures projects.

WHAT PIs SHOULD EXPECT

- Partner with NewCures to determine the milestones that would add value to their therapeutic asset to attract third party interest. NewCures will actively consult with seasoned external experts to evaluate and plan strategic developmental path.
- Work with NewCures to provide sufficient compound material for third party entities to generate key pre-clinical data, i.e., proof-of-concept validation. NewCures will manage the details of the experiments and data collection from CROs to add external validation.
- Engage with INVO and NewCures to explore subsequent commercialization avenues. If external partnerships are generated, some possible outcomes may be licensing opportunities or startup formation.

Contact: Caroline Ko, PhD | Project Leader, NewCures | 847.491.2163 | c-ko@northwestern.edu

<http://www.invo.northwestern.edu/startup-resources/funding/newcures.html>